Company / Cash per Share
SAB Biotherapeutics, Inc. Cash per Share History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash per Share
$1.13
FY2025
5-year range
$0.49 / $11.22
FY2021-FY2025
Trend
+17.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $11.22 to $1.13 over the past 2 years.
Based on SEC 10-K filings.
1.13 in FY2025 with a 3-year CAGR of -4.0%.
Declined from $11.22 to $1.13 over the past 2 years.
Cash per Share over time
Growth rates
- 3-Year CAGR
- -4.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, cash per share increased 17.2% year-over-year.
- Peak cash per share was recorded in FY2023.
- Lowest cash per share in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.31 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.13 | +17.2% |
| FY2024 | $0.96 | -91.4% |
| FY2023 | $11.22 | +777.8% |
| FY2022 | $1.28 | +163.3% |
| FY2021 | $0.49 | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026